Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/21467
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAnderson, Nigel J-
dc.contributor.authorJackson, James E-
dc.contributor.authorWada, Morikatsu-
dc.contributor.authorSchneider, Michal-
dc.contributor.authorPoulsen, Michael-
dc.contributor.authorRolfo, Maureen-
dc.contributor.authorFahandej, Maziar-
dc.contributor.authorGan, Hui K-
dc.contributor.authorKhoo, Vincent-
dc.date2019-08-06-
dc.date.accessioned2019-08-12T05:00:35Z-
dc.date.available2019-08-12T05:00:35Z-
dc.date.issued2019-08-06-
dc.identifier.citationJournal of medical radiation sciences 2019; online first: 6 August-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/21467-
dc.description.abstractPrecision radiotherapy relies heavily on optimal weight management. Our group previously developed a risk stratification model for patients at risk of prolonged feeding tube (FT) intervention. The study objective was to assess on-treatment weight loss according to stratified risk of prolonged FT use. One hundred and one (n = 101) definitive head and neck radiotherapy patients were included in this study. Patients were stratified into high risk (HRi: T-classification ≥ 3 with level 2 Nodal disease), high-intermediate risk (HIRi: T-classification ≥ 3 without level 2 Nodes) and low-intermediate risk (LIRi: T-classification < 3 with level 2 Nodes) of prolonged FT use. Demographic variables and on-treatment weight loss were evaluated according to risk status. Oropharyngeal carcinoma (OPC) was present in a larger proportion in the LIRi cohort (HRi: 71%, HIRi: 52%, LIRi: 81%, P = 0.008). LIRi patients were more likely to have human papilloma virus (HPV)-associated disease (88%, P = 0.001). Never/minimal smoking (P = 0.003), good performance status (P < 0.001), healthy BMI (P = 0.050) and no pre-existing dysphagia (P < 0.001) were predominant within the LIRi prognostic group. LIRi patients lost significantly more weight in total (HRi = 4.8% vs. LIRi = 8.2%, P = 0.002; HIRi = 5.2% vs. LIRi = 8.2%, P = 0.006) and when using a FT (HRi = 4.6% vs. LIRi = 8.8%, P < 0.001; HIRi = 5.3% vs. LIRi = 8.8%, P = 0.002). Patients identified as low-intermediate risk of prolonged, ≥25% FT use report significantly increased weight loss compared with patients at higher risk of FT use. This cohort is typical of the increasing number of patients presenting with HPV-associated OPC. Results of this study suggest we should closely observe such patients throughout treatment, to ensure optimal weight maintenance, facilitating precision radiotherapy.-
dc.language.isoeng-
dc.subjectfeeding tube-
dc.subjecthead and neck cancer-
dc.subjectintensity modulated radiotherapy-
dc.subjecttoxicity-
dc.subjectweight loss-
dc.titleThe changing landscape of head and neck cancer radiotherapy patients: is high-risk, prolonged feeding tube use indicative of on-treatment weight loss?-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of medical radiation sciences-
dc.identifier.affiliationDepartment of Palliative Care, St Vincent's Hospital, Fitzroy, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationFaculty of Medicine, The University of Queensland, Herston, Queensland, Australiaen
dc.identifier.affiliationRadiation Oncology Centres, Gold Coast University Hospital, Gold Coast, Queensland, Australiaen
dc.identifier.affiliationDepartment of Clinical Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Chelsea, London, UKen
dc.identifier.affiliationFaculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australiaen
dc.identifier.affiliationSchool of Medicine, Griffith University, Gold Coast, Queensland, Australiaen
dc.identifier.affiliationDepartment of Medical Imaging and Radiation Sciences, Monash University, Monash, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1002/jmrs.349-
dc.identifier.orcid0000-0002-4826-2339-
dc.identifier.pubmedid31385650-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.